Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,382 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Analysis of elderly patients, aged 60 years old or over, with acute lymphoblastic leukemia].
Nagura E, Minami S, Nagata K, Morishita Y, Takeyama H, Sao H, Suzuki H, Naoe T, Yokomaku S, Mizuno H, Murase T, Hirabayashi N, Shirokawa Y, Tanimoto M, Kawashima K, Saito H. Nagura E, et al. Among authors: kawashima k. Nihon Ronen Igakkai Zasshi. 1999 Jan;36(1):52-8. doi: 10.3143/geriatrics.36.52. Nihon Ronen Igakkai Zasshi. 1999. PMID: 10332195 Free article. Clinical Trial. Japanese.
Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia.
Nagura E, Kimura K, Yamada K, Ohta K, Maekawa T, Takaku F, Uchino H, Masaoka T, Amaki I, Kawashima K, et al. Nagura E, et al. Among authors: kawashima k. Cancer Chemother Pharmacol. 1994;34(1):23-9. doi: 10.1007/BF00686107. Cancer Chemother Pharmacol. 1994. PMID: 8174198 Clinical Trial.
Nation-wide randomized comparative study of doxorubicin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia.
Nagura E, Kimura K, Yamada K, Ota K, Maekawa T, Takaku F, Uchino H, Masaoka T, Amaki I, Kawashima K, et al. Nagura E, et al. Among authors: kawashima k. Cancer Chemother Pharmacol. 1994;33(5):359-65. doi: 10.1007/BF00686263. Cancer Chemother Pharmacol. 1994. PMID: 8306408 Clinical Trial.
A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma.
Nagura E, Ichikawa A, Kamiya O, Kato R, Utsumi M, Tanaka M, Takeyama H, Shimizu K, Kobayashi M, Naito K, Nishiwaki H, Mizuno H, Hirabayashi N, Nitta M, Kato Y, Shibata T, Hotta T, Kawashima K, Saito H. Nagura E, et al. Among authors: kawashima k. Cancer Chemother Pharmacol. 1997;39(4):279-85. doi: 10.1007/s002800050573. Cancer Chemother Pharmacol. 1997. PMID: 9025767 Clinical Trial.
Posttreatment M-protein nadir level is a significant prognostic factor associated with survival in multiple myeloma. Nagoya Myeloma Cooperative Study Group.
Shimizu K, Kamiya O, Hirabayashi N, Ichikawa A, Kawashima K, Kobayashi M, Mizuno H, Nagura E, Nitta M, Saito H, Sao H, Shibata T, Takeyama H. Shimizu K, et al. Among authors: kawashima k. Jpn J Cancer Res. 1999 Mar;90(3):355-60. doi: 10.1111/j.1349-7006.1999.tb00755.x. Jpn J Cancer Res. 1999. PMID: 10359052 Free PMC article.
1,382 results